Sub-pluripotent Stem Cells
- sean xiao
- Nov 11, 2024
- 2 min read
Project Overview
We have pioneered groundbreaking research in the field of adult stem cells, focusing on using fetal tissue to develop sub-pluripotent stem cells, a novel subpopulation with pluripotency close to embryonic stem cells and safety akin to normal cells. By proposing the "Sub-Pluripotent Stem Cell Theory," we have contributed significantly to scientific advancements, publishing over 380 papers, authoring foundational monographs, and establishing China’s first scalable production process for adult stem cells. In 2004, we successfully registered and initiated clinical trials for the world’s first stem cell-based new drug, marking a major milestone in China’s scientific innovation.
About the Product
Our stem cell product is based on sub-pluripotent stem cells, a breakthrough type of adult stem cell with the following attributes:
High Pluripotency: Differentiation potential comparable to embryonic stem cells, enabling versatile tissue regeneration.
Safety: Matches the safety profile of normal somatic cells, avoiding ethical controversies and safety concerns associated with embryonic stem cells.
Immunomodulatory Function: Dual-directional regulation capability, promoting immune balance by inducing regulatory dendritic cells (DCs) and mitigating hyperinflammatory responses.
Scalable Production: Developed using engineered preparation processes to ensure large-scale production with consistent quality.
Therapeutic Versatility: Addressing medical needs in immune disorders, organ rejection, and chronic inflammatory diseases.
This product is the first stem cell-based new drug approved for clinical trials globally, laying the foundation for innovative approaches in regenerative medicine and immunotherapy.
Application Scenario
Our research and development efforts focus on creating solutions for critical medical challenges, including:
Immune Regulation: Balancing immune responses to treat organ rejection, autoimmune diseases, and inflammatory conditions.
Tissue Regeneration: Repairing and restoring damaged tissues in degenerative or chronic diseases.
Disease Management: Developing innovative therapies for major health conditions such as cancer and immune-related disorders.
The versatility of our stem cell technology positions it as a transformative tool for advancing global healthcare.
Project Advantages
Innovative Discovery: Introduced the world’s first sub-pluripotent stem cell with near-embryonic capabilities and unmatched safety.
Technical Breakthroughs: Overcame key challenges to achieve scalable production, controlled immunomodulation, and engineered preparation processes.
Academic Leadership: Produced globally recognized research, earning extensive citations and international acclaim.
Clinical Pioneering: Successfully registered and conducted trials for the world’s first stem cell drug, demonstrating its safety and efficacy.
Strategic Impact: Positioned China as a leader in stem cell research, driving innovation in healthcare and developing a globally competitive stem cell-based pharmaceutical industry.
